

PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 63687

Title: Current Cancer Therapies And Their Influence On Glucose Control

Reviewer's code: 02624433

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: South Korea

Author's Country/Territory: Canada

Manuscript submission date: 2021-02-07

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-02-08 01:11

Reviewer performed review: 2021-03-02 02:26

Review time: 22 Days and 1 Hour

Scientific quality	[<input checked="" type="radio"/>] Grade A: Excellent [<input type="radio"/>] Grade B: Very good [<input type="radio"/>] Grade C: Good [<input type="radio"/>] Grade D: Fair [<input type="radio"/>] Grade E: Do not publish
Language quality	[<input checked="" type="radio"/>] Grade A: Priority publishing [<input type="radio"/>] Grade B: Minor language polishing [<input type="radio"/>] Grade C: A great deal of language polishing [<input type="radio"/>] Grade D: Rejection
Conclusion	[<input checked="" type="radio"/>] Accept (High priority) [<input type="radio"/>] Accept (General priority) [<input type="radio"/>] Minor revision [<input type="radio"/>] Major revision [<input type="radio"/>] Rejection
Re-review	[<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No

SPECIFIC COMMENTS TO AUTHORS

Thank you for submitting excellent manuscript to this journal.

PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 63687

Title: Current Cancer Therapies And Their Influence On Glucose Control

Reviewer's code: 03782335

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Kosovo

Author's Country/Territory: Canada

Manuscript submission date: 2021-02-07

Reviewer chosen by: Jia-Ping Yan

Reviewer accepted review: 2021-02-13 12:13

Reviewer performed review: 2021-03-05 00:23

Review time: 19 Days and 12 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Hyperglycemia and its complications is an adverse effect of different agents used in cancer patients. Its prompt identification is important for clinicians, since its presence might affect the prognosis for the patients. Authors of this manuscript have tried to unveil what is known regarding this theme, though some issues remain: 1. The important sentence "Hyperglycemia is a common and potentially significant adverse effect arising from the use of several widely applied cancer therapeutic classes including immune checkpoint inhibitors, PI3K/AKT/mTOR inhibitors, 5-Fluorouracil analogs, and glucocorticoids" needs to be backed by references. 2. Please discuss the relationship between time length of drug use (where possible) and hyperglycemia risk. Include this information in tables. 3. Drugs which act on mTOR pathway can act on two protein supercomplexes, that is mTORC1 and mTORC2, alone or in combination. These two supercomplexes do not exert identical cellular actions. Please dissect this role of mTOR inhibitors in this context and the importance of mTORC1 and mTORC2 inhibition alone and in combination. 4. Please include information regarding the relationship between drug doses (where possible) and hyperglycemia, and what are cut-off values (where possible) which increase significantly the risk from hyperglycemia. Also, compare cut-off values for hyperglycemia risk and standard doses used in cancer patients of the drugs discussed in this review. 5. Please include information in the manuscript and tables regarding individual drug risk for hyperglycemia in respective drug classes. For example, ipilimumab is much safer in this respect in its class compared to pembrolizumab. Include an illustration which summarizes how cellular pathways are affected by the drugs discussed in this review, which changes eventually cause hyperglycemia. Also, discuss more thoroughly regarding the details of cellular biochemical changes associated with hyperglycemia from drug use.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Diabetes

Manuscript NO: 63687

Title: Current Cancer Therapies And Their Influence On Glucose Control

Reviewer's code: 03782335

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Kosovo

Author's Country/Territory: Canada

Manuscript submission date: 2021-02-07

Reviewer chosen by: Man Liu

Reviewer accepted review: 2021-04-12 07:33

Reviewer performed review: 2021-04-29 02:46

Review time: 16 Days and 19 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

I would like to thank authors for their work during the process of review, which in my

opinion, has resulted in improvement of an already solid manuscript. I don't have further comments to this manuscript.